Anthony Hunter, MD

Anthony M. Hunter, MD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A hematologist hematologist: (hee-muh-TOL-uh-jist) A doctor who specializes in treating blood diseases and disorders of blood producing organs. , Dr. Hunter specializes in treating patients with leukemia and other myeloid malignancies including myeloproliferative neoplasms, myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at… and myelodysplastic/myeloproliferative neoplasms.

Dr. Hunter holds professional memberships with American Society of Clinical Oncology, American Society of Hematology, and Society of Hematologic Oncology.

Dr. Hunter received his Medical Degree from Medical College of Wisconsin in Milwaukee, Wisconsin. He completed his residency in internal medicine at Emory University School of Medicine in Atlanta, Georgia. He completed a fellowship in hematology and medical oncology at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, where he served as Chief Fellow in his final year.

Dr. Hunter's research interests focus on understanding the molecular drivers of myeloid malignancies in order to improve prognostication and develop novel treatment strategies. He participates in clinical trials clinical trials: Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study. Understanding Clinical Trials Clinical… evaluating novel therapies in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. He is also co-investigator of a large, international effort to develop a novel prognostic system in chronic myelomonocytic leukemia.